OrgaNext Research BV is the first Life Science Company dedicated to prevention and treatment of unwanted muscle loss.
OrgaNext Research is developing Recovery Booster therapies; a new class of prescription drugs that support the recovery process by stimulating the proliferation of satellite cells, also known as new muscle cells. Muscle mass plays a key role in recovery from illness or trauma. Muscle strength and function is vital to the physical recovery process. Satellite cells, the stem cells of skeletal muscle, are normally activated upon injury of exercise, but gradually fail to do so as we age. Elderly hospitalized patients can lose up to 10% of muscle mass in only three days. In vitro studies with NDD, OrgaNext Research’s proprietary compound, have demonstrated that NDD stimulates the proliferation of new skeletal muscle cells in both young and old human muscle cell-lines. Recovery after Hip Fracture, will be the first indication for NDD, addressing an urgent unmet medical need in our aging society.
OrgaNext Research BV is developing NDD, the novel combination of Nandrolone Decanoate (ND) and Vitamin D3 (D) in a concomital subcutaneous formulation. NDD is the first prescription medicine to support the recovery of frail elderly after hospitalization or surgery. The recovery after hip fracture will be the first indication for NDD.